Skip to main content
Isaac Francis Photo
Isaac Francis

Isaac Francis

GrafaFinance Journalist

Finance journalist at Grafa. Covers tech, crypto, and markets, making complex finance clear for all. Passionate about innovation and trends.

Articles by Isaac Francis

Grafa

TOMI Environmental solutions posts strong sequential revenue Growth in preliminary Q1 results

TOMI Environmental Solutions (NASDAQ:TOMZ), a global provider of disinfection and decontamination essentials, announced preliminary unaudited financial results for the first quarter of 2026 on April 8, highlighting a 67% sequential revenue increase over the fourth quarter of 2025.

Read more: TOMI Environmental solutions posts strong sequential revenue Growth in preliminary Q1 results
Grafa
Industrials

Atkore divests HDPE pipe business to Infra Pipes in strategic portfolio realignment

Atkore (NYSE:ATKR) announced on April 8, 2026, the sale of its High-Density Polyethylene (HDPE) pipe and conduit business to Infra Pipes, a prominent North American manufacturer of polyethylene pipeline solutions.

Read more: Atkore divests HDPE pipe business to Infra Pipes in strategic portfolio realignment
Grafa

FDA grants orphan drug designation to Plus Therapeutics’ REYOBIQ

Plus Therapeutics (NASDAQ:PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics for central nervous system (CNS) cancers, announced on April 8, 2026, that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to REYOBIQ™ (rhenium Re186 obisbemeda).

Read more: FDA grants orphan drug designation to Plus Therapeutics’ REYOBIQ
Grafa

Hemispherian launches first-in-human trial for glioblastoma therapy GLIX1

Hemispherian, a clinical-stage oncology company, announced on April 8, 2026, the initiation of a Phase 1/2a clinical trial for its lead candidate, GLIX1, marking a significant milestone in the development of targeted therapies for recurrent and progressive glioblastoma (GBM) and other high-grade gliomas.

Read more: Hemispherian launches first-in-human trial for glioblastoma therapy GLIX1